1. Home
  2. PRFX vs AZTR Comparison

PRFX vs AZTR Comparison

Compare PRFX & AZTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PainReform Ltd.

PRFX

PainReform Ltd.

HOLD

Current Price

$0.89

Market Cap

2.7M

Sector

Health Care

ML Signal

HOLD

Logo Azitra Inc

AZTR

Azitra Inc

HOLD

Current Price

$0.30

Market Cap

3.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRFX
AZTR
Founded
2007
2014
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7M
3.2M
IPO Year
2020
2023

Fundamental Metrics

Financial Performance
Metric
PRFX
AZTR
Price
$0.89
$0.30
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$4.00
AVG Volume (30 Days)
95.3K
339.1K
Earning Date
02-27-2026
02-23-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.61
$0.26
52 Week High
$6.65
$4.33

Technical Indicators

Market Signals
Indicator
PRFX
AZTR
Relative Strength Index (RSI) 49.84 42.93
Support Level $0.66 $0.26
Resistance Level $0.74 $0.32
Average True Range (ATR) 0.06 0.02
MACD 0.01 0.01
Stochastic Oscillator 74.46 52.08

Price Performance

Historical Comparison
PRFX
AZTR

About PRFX PainReform Ltd.

PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.

About AZTR Azitra Inc

Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.

Share on Social Networks: